FDA Webview Site FDA Review Site FDA Updater Site
header.gif
Username:
Password:
 

human drugs
animal drugs
biologics
eirs 483s
medical devices
marketing
email
search our site
  
FDA-RELATED NEWS
 
<< Prev  7 8 9 10 11 12 13 14 15 16 17
 
TXT Boxed Warning for Veozah Liver Injury
01/02/2025
 
 
TXT Lexicon Dropping Zynquista After CRL
01/02/2025
 
 
TXT NEWSROOM CLOSED FOR THE HOLIDAYS
12/14/2024
 
 
TXT Zimmer Biomet Stemless Shoulder System
12/13/2024
 
 
TXT CDER Right-to-Try Summaries Can Go Thru Portal
12/13/2024
 
 
TXT Guide on Tech Specs for NASH Drug Data Sets
12/13/2024
 
 
TXT FDA Promotes Centralized Statistical Trial Monitoring
12/13/2024
 
 
TXT McKinsey & Co. Pays $650 Million in Opioid Case
court
12/13/2024
 
 
TXT Syndax Leukemia Review Extended by FDA
07/29/2024
 
 
TXT NEWSROOM CLOSED FOR THE HOLIDAYS
12/18/2023
 
 
TXT FDA OKs Merck Kidney Cancer Drug
12/17/2023
 
 
TXT FDA OKs Glaukos Intraocular Pressure Drug Implant
12/17/2023
 
 
TXT 2 Imbruvica Accelerated Approvals Withdrawn
12/17/2023
 
 
TXT DTC Survey Examines Quantitative Claims
12/17/2023
 
 
TXT FDA Updates Breast Implant Safety Info
12/17/2023
 
 
TXT Guide on Priority Zoonotic Animal Drugs
12/17/2023
 
 
TXT Moderna Inspection Cites GMP Issues: Report
12/17/2023
 
 
TXT FDA Warns Makers of Illegal Animal Antimicrobials
12/14/2023
 
 
TXT FDA in 3 More Collaborative Communities
12/14/2023
 
 
TXT House Committee Threatens FDA Subpoena
12/14/2023
 
 
TXT FDA ‘Doing Little’ on Social Media Drug Claims: Report
12/14/2023
 
 
TXT Pharmasol Permanent Injunction Approved
12/14/2023
 
 
TXT Clinical Hold on 3 CARsgen CAR T-cell Therapies
12/14/2023
 
 
TXT Stakeholder Technical Issues with Ophthalmic Guide
12/14/2023
 
 
TXT FDA Approves Neuroblastoma Drug
12/14/2023
 
 
TXT Update GAO Device Recall Oversight Report: Senators
12/13/2023
 
 
TXT Novid Distributing Unapproved, Misbranded Drug: FDA
12/13/2023
 
 
TXT Guide on Advanced Manufacturing Tech
12/13/2023
 
 
TXT Regulatory Affairs, Foods Program Under Review
12/13/2023
 
 
TXT HELP Committee OKs EFFECTIVE Opioid Bill
12/13/2023
 
 
TXT GOP Senators Urge Increase in Foreign Inspections
12/13/2023
 
 
TXT Amgen Files Priority BLA for Lung Cancer
12/13/2023
 
 
TXT AdvaMed Faults FDA on ‘Safety’ 510(k) Guidances
12/13/2023
 
 
TXT Supreme Court Agrees to Hear Mifepristone Case
12/13/2023
 
 
TXT FDA OK’s Ferring’s Bladder Cancer Gene Therapy
12/16/2022
 
 
TXT Panel to Examine Ongoing Covid Vaccine Modifications
12/16/2022
 
 
TXT Contractor Conflict-of Interest Bill Passes Congress
12/16/2022
 
 
TXT Aurigene Ditches Psoriasis Drug Candidate
12/16/2022
 
 
TXT Providence Medical Tech Cavux Facet Device Cleared
12/16/2022
 
 
TXT Draft Guide on Pulmonary Tuberculosis Drugs
12/15/2022
 
 
TXT Draft Inspection Refusal Guidance
12/15/2022
 
 
TXT FDA Stem Cell Therapy Regulation at Risk: Attorneys
12/15/2022
 
 
TXT FDA Updates CRL Guidance Performance Goals
12/15/2022
 
 
TXT Comments on Immune-Mediated Adverse Reaction Guidance
12/15/2022
 
 
TXT Independent FDA Needed to Stop Political Meddling: GAO
12/15/2022
 
 
TXT States Pushing for Canadian Drug Imports: Report
12/14/2022
 
 
TXT Harmonize Innovative Manufacturing Regulation: PhRMA
12/14/2022
 
 
TXT AdvaMed Supports Breakthrough Device Guidance Updates
12/14/2022
 
 
TXT VALID Could Hurt Home Sample Testing: Attorneys
12/14/2022
 
 
TXT Former NECC Ops Director Sentenced to 5 Months in Jail
12/14/2022
 
 
TXT FDA Panel Thumbs Down on Heart Failure Drug
12/14/2022
 
 
TXT FDA Accepts NDA for Eye Dilating Combo Product
12/13/2022
 
 
TXT $2.25 mil. RWD Funding Opportunity
12/13/2022
 
 
TXT CGMP Deviations Seen in Centrient Inspection
12/13/2022
 
 
TXT Clinicians Need Refresher on Clinical Trial Statistics: Survey
12/13/2022
 
 
TXT What’s Behind the New LASIK Guidance?
12/13/2022
 
 
TXT Assign TE Codes for All Approved Drugs: Study
12/13/2022
 
 
TXT Change Antibiotic Development Incentives: Study
12/13/2022
 
 
TXT Moderna/Merck Cancer Vaccine Meets Endpoint
12/13/2022
 
 
TXT Doc Group Wants FDA Probe of Musk’s Neuralink
12/13/2022
 
 
<< Prev  7 8 9 10 11 12 13 14 15 16 17 
 
The most authoritative FDA news analysis each week is found in the pages of Dickinson's FDA Review. Since 1984, this newsletter has been providing in-depth reports on the most significant FDA developments affecting the pharmaceutical, medical device, biologics and veterinary medicines industries. Unlike other media, FDA Review eliminates time-wasting minutia and presents in clear, concise language the essence of what's really important - and why. It is the publication that FDA officials themselves read. Delivered in the middle of each week, FDA Review presents:
  • The latest agency policy developments, often before they're officially announced;
  • Major news insights, follow-ups and reactions in each product area;
  • Summaries of the latest Warning Letters;
  • The newest product approvals;
  • Summaries of the latest FDA Federal Register notices;
  • Summaries of DDMAC letters;
  • Related industry news capsules;
  • The industry's most concise FDA news index;
  • Inside-FDA news briefs
You can rely on FDA Review to provide only what's important - in the most convenient and time-saving